Benefits of cannabidiol from Cannabis sativa on neurodegenerative illnesses: a review on its implementation in modern medicine
Article Sidebar
Main Article Content
Abstract
Cannabidiol is one of the most abundant compounds of Cannabis sativa, and it’s extremely important due to its high medical potential, especially in reference to neurodegenerative illnesses. Through physiological intervention carried out by the endocannabinoid system and its antioxidant properties, it's able to prevent phenomena such as neuronal apoptosis, and its able to assist with the management of the most prevalent symptoms, namely inflammation, pain and accumulation of toxic secondary compounds, of illnesses such as Alzheimer’s Disease, Parkinson’s Disease and Dementia. On the other hand, bioavailability, adverse effects, and personal beliefs correspond to factors that make the implementation of CBD in medications difficult. Finally, despite the fact that CBD presents ample benefits, it’s necessary to improve administration routes, the mitigation of unwanted side effects, and to change the social perception of the medical use of Cannabis sativa in order to allow the implementation of CBD as a regular treatment for neurodegenerative illnesses.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores conservan los derechos de autor y ceden a la revista el derecho de la primera publicación y pueda editarlo, reproducirlo, distribuirlo, exhibirlo y comunicarlo en el país y en el extranjero mediante medios impresos y electrónicos. Asimismo, asumen el compromiso sobre cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Editorial Tecnológica de Costa Rica. Además, se establece que los autores pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
How to Cite
References
[1] S. A. Syed et al., “International perspectives on physician knowledge, attitudes, and practices related to medical cannabis,” Frontiers in Public Health, vol. 13, p. 1463871, 2025, https://doi.org/10.3389/fpubh.2025.1463871.
[2] M. Savio, H. Kearney, y E. J. Downer, “Neurologists’ perspectives of cannabis-based medicines: results from an all-Ireland survey,” Irish Journal of Medical Science, vol. 194, no. 2, pp. 687-697, 2025, https://doi.org/10.1007/s11845-025-03880-0
[3] P. Sharma et al., “Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study,” PEC Innovation, vol. 1, p. 100044, Dic. 2022, https://doi.org/10.1016/j.pecinn.2022.100044
[4] S. Dahlke et al., “The Effects of Stigma: Older Persons and Medicinal Cannabis,” Qualitative Health Research, vol. 34, no. 8–9, pp. 717-731, Jul. 2024, https://doi.org/10.1177/10497323241227419
[5] S. Dahlke et al., “Understanding Older Adults’ Experiences with Cannabis for Medicinal Purposes: A Mixed Methods Study,” Canadian Journal on Aging / La Revue canadienne du vieillissement, vol. 44, no. 1, pp. 10–19, Mar. 2025, https://doi.org/10.1017/S0714980824000357
[6] F. T. Avoseh, F. M. Mtunzi, O. N. Avoseh, y S. Takaidza, “Cannabis sativa; Ethnobotanicals, Classifications, Pharmacology, and Phytochemistry,” Natural Product Communications, vol. 20, no. 6, Jun. 2025, https://doi.org/10.1177/1934578X251334244
[7] Y. Yang, R. Vyawahare, M. Lewis-Bakker, H. A. Clarke, A. H. C. Wong, y L. P. Kotra, “Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors,” Molecules, vol. 25, no. 15, p. 3466, Jul. 2020, https://doi.org/10.3390/molecules25153466
[8] K. M. Nelson et al., “The Essential Medicinal Chemistry of Cannabidiol (CBD),” Journal of Medicinal Chemistry, vol. 63, no. 21, pp. 12137–12155, Nov. 2020, https://doi.org/10.1021/acs.jmedchem.0c00724
[9] A. K. Schlag, C. Hindocha, R. Zafar, D. J. Nutt, y H. V. Curran, “Cannabis based medicines and cannabis dependence: A critical review of issues and evidence,” Journal of psychopharmacology (Oxford, England), vol. 35, no. 7, pp. 773–785, Jul. 2021, https://doi.org/10.1177/0269881120986393
[10] T. Cassano et al., “From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases,” Frontiers in Pharmacology, vol. 11, p. 515092, Mar. 2020, https://doi.org/10.3389/fphar.2020.00124
[11] N. Martinez Naya et al., “An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects,” Molecules, vol. 29, no. 2, p. 473, Ene. 2024, https://doi.org/10.3390/molecules29020473
[12] G. Madeo, A. Kapoor, R. Giorgetti, F. P. Busardò, y J. Carlier, “Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review,” Current neuropharmacology, vol. 21, no. 11, pp. 2323–2342, Mar. 2023, https://doi.org/10.2174/1570159X21666230322143401
[13] D. M. Wilson, M. R. Cookson, L. van den Bosch, H. Zetterberg, D. M. Holtzman, y I. Dewachter, “Hallmarks of neurodegenerative diseases,” Cell, vol. 186, no. 4, pp. 693–714, Feb. 2023, https://doi.org/10.1016/j.cell.2022.12.032
[14] R. Armstrong, “What causes neurodegenerative disease?,” Folia neuropathologica, vol. 58, no. 2, pp. 93–112, Jun. 2020, https://doi.org/10.5114/fn.2020.96707
[15] Z. Breijyeh, R. Karaman, D. Muñoz-Torrero, y R. Dembinski, “Comprehensive Review on Alzheimer’s Disease: Causes and Treatment,” Molecules, vol. 25, no. 24, p. 5789, Dic. 2020, https://doi.org/10.3390/molecules25245789
[16] R. N. L. Lamptey, B. Chaulagain, R. Trivedi, A. Gothwal, B. Layek, y J. Singh, “A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics,” International Journal of Molecular Sciences, vol. 23, no. 3, p. 1851, Feb. 2022, https://doi.org/10.3390/ijms23031851
[17] A. Duranti et al., “The Endocannabinoid System as a Target for Neuroprotection/Neuroregeneration in Perinatal Hypoxic–Ischemic Brain Injury,” Biomedicines, vol. 11, no. 1, p. 28, Ene. 2022, https://doi.org/10.3390/biomedicines11010028
[18] S. Schilling, R. Melzer, y P. F. McCabe, “Cannabis sativa,” Current Biology, vol. 30, no. 1, pp. R8–R9, Ene. 2020, https://doi.org/10.1016/j.cub.2019.10.039
[19] N. Martinez Naya, J. Kelly, G. Corna, M. Golino, A. Abbate, y S. Toldo, “Molecular and Cellular Mechanisms of Action of Cannabidiol,” Molecules, vol. 28, no. 16, p. 5980, Ago. 2023, https://doi.org/10.3390/molecules28165980
[20] E. D. Mock, B. Gagestein, y M. van der Stelt, “Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities,” Progress in Lipid Research, vol. 89, p. 101194, Ene. 2023, https://doi.org/10.1016/j.plipres.2022.101194
[21] A. Houldsworth, “Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants,” Brain communications, vol. 6, no. 1, 2024, https://doi.org/10.1093/braincomms/fcad356
[22] P. Wen et al., “Oxidative stress and mitochondrial impairment: Key drivers in neurodegenerative disorders,” Ageing Research Reviews, vol. 104, p. 102667, Feb. 2025, https://doi.org/10.1016/J.ARR.2025.102667.
[23] S. Bhunia, N. Kolishetti, A. Y. Arias, A. Vashist, y M. Nair, “Cannabidiol for neurodegenerative disorders: A comprehensive review,” Frontiers in Pharmacology, vol. 13, p. 989717, Oct. 2022, https://doi.org/10.3389/FPHAR.2022.989717
[24] M. Ożarowski, T. M. Karpiński, A. Zielińska, E. B. Souto, y K. Wielgus, “Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action,” International Journal of Molecular Sciences 2021, vol. 22, no. 9, p. 4294, Abr. 2021, https://doi.org/10.3390/IJMS22094294.
[25] S. Khosropoor, M. S. Alavi, L. Etemad, y A. Roohbakhsh, “Cannabidiol goes nuclear: The role of PPARγ,” Phytomedicine, vol. 114, p. 154771, Jun. 2023, https://doi.org/10.1016/J.PHYMED.2023.154771.
[26] A. Vasincu et al., “Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty,” Biology, vol. 11, no. 3, p. 440, Mar. 2022, https://doi.org/10.3390/BIOLOGY11030440.
[27] A. Pugazhendhi et al., “Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review,” Process Biochemistry, vol. 111, pp. 9–31, Dic. 2021, https://doi.org/10.1016/J.PROCBIO.2021.08.025.
[28] C. Cattaneo y W. H. Jost, “Pain in Parkinson’s Disease: Pathophysiology, Classification and Treatment,” Journal of integrative neuroscience, vol. 22, no. 5, 2023, https://doi.org/10.31083/J.JIN2205132.
[29] K. Singh et al., “Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review,” Behavioural Neurology, vol. 2023, no. 1, p. 8825358, Ene. 2023, https://doi.org/10.1155/2023/8825358.
[30] S. Latif et al., “Dopamine in Parkinson’s disease,” Clinica Chimica Acta, vol. 522, pp. 114–126, Nov. 2021, https://doi.org/10.1016/J.CCA.2021.08.009.
[31] K. R. Gandhi y A. Saadabadi, “Levodopa (L-Dopa),” Encyclopedia of Psychopharmacology, pp. 898–899, Abr. 2023, https://doi.org/10.1007/978-3-642-36172-2_200303.
[32] L. di Biase, P. M. Pecoraro, S. P. Carbone, M. L. Caminiti, y V. di Lazzaro, “Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions,” Journal of Clinical Medicine, vol. 12, no. 13, p. 4427, Jun. 2023, https://doi.org/10.3390/JCM12134427.
[33] S. Silvestro, G. Schepici, P. Bramanti, y E. Mazzon, “Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease,” Molecules, vol. 25, no. 21, p. 5186, Nov. 2020, https://doi.org/10.3390/MOLECULES25215186.
[34] P. D. Emmady, C. Schoo, and P. Tadi, Major Neurocognitive Disorder (Dementia). Treasure Island: StatPearls Publishing, 2022. Accedido: Sept. 27, 2025. [En línea]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK557444/
[35] S. Pautex et al., “Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients,” Frontiers in Aging Neuroscience, vol. 14, p. 957665, Sept. 2022, https://doi.org/10.3389/fnagi.2022.957665
[36] F. Bianchi et al., “Medical cannabinoids for painful symptoms in patients with severe dementia: a randomized, double-blind cross-over placebo-controlled trial protocol,” Frontiers in Pain Research, vol. 4, p. 1108832, 2023, https://doi.org/10.3389/FPAIN.2023.1108832.
[37] M. Schouten, S. Dalle, D. Mantini, y K. Koppo, “Cannabidiol and brain function: current knowledge and future perspectives,” Frontiers in pharmacology, vol. 14, 2024, https://doi.org/10.3389/FPHAR.2023.1328885.
[38] E. Chesney et al., “Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials,” Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, vol. 45, no. 11, pp. 1799–1806, Oct. 2020, https://doi.org/10.1038/S41386-020-0667-2.
[39] J. D. R. Souza et al., “Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022),” Pharmaceutics, vol. 14, no. 12, p. 2598, Dic. 2022, https://doi.org/10.3390/pharmaceutics14122598